 ATLANTA--BUSINESS WIRE--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. Since our initial public offering in December 2020, the Virios Therapeutics team has made significant operational progress to ensure the c 